Home > News > Can Medical Nanotechnology Shorten Clinical Trials and Regulatory Pathways?
September 13th, 2005
Can Medical Nanotechnology Shorten Clinical Trials and Regulatory Pathways?
Nanotechnology is poised to enable advances that could be utilized to shave time and expense from multiple stages of the drug discovery and development efforts.
Ohio State University
National Cancer Institute
Harris & Harris Group Portfolio Company D-Wave Systems Announces 1,000 Qubit Processor and is Discussed in the Economist June 23rd, 2015
Global Nanoclays Market Analysis, Size, Growth, Trends And Segment Forecasts, 2015 To 2022: Grand View Research, Inc June 15th, 2015
Healthcare Nanotechnology (Nanomedicine) Market Size To 2020 June 5th, 2015
Environmental Issues to Hamper Growth of Global Nanocomposites Market June 4th, 2015
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Carnegie Mellon chemists characterize 3-D macroporous hydrogels: Methods will allow researchers to develop new 'smart' materials June 30th, 2015
Chitosan coated, chemotherapy packed nanoparticles may target cancer stem cells June 30th, 2015
Researchers from the UCA, key players in a pioneering study that may explain the origin of several digestive diseases June 30th, 2015